List of Excipients in Branded Drug DESFERAL

« Back to Dashboard

Desferal Excipient Strategy and Commercial Opportunities for Deferoxamine Mesylate

Last updated: August 30, 2026

Desferal is the originator brand of deferoxamine mesylate, an iron-chelating agent supplied as a sterile powder for injection. Its commercial protection is mature, and the principal opportunity is no longer a new-molecule patent position. Value is concentrated in excipient-free sterile manufacturing, reconstitution convenience, container-closure performance, administration devices, stability, and differentiated hospital supply models. Deferoxamine has no biosimilar pathway because it is a chemically defined small molecule. Generic injectable competition and alternative chelators, particularly deferasirox and deferiprone, limit pricing power.

What is Desferal and how is it administered?

Desferal contains deferoxamine mesylate and is indicated for acute iron intoxication and chronic iron overload associated with transfusion-dependent anemias and other conditions involving iron accumulation.[1]

Attribute	Desferal profile
Active ingredient	Deferoxamine mesylate
Therapeutic class	Iron chelator
Dosage form	Sterile powder for injection
Principal routes	Subcutaneous infusion, intravenous infusion, intramuscular injection
U.S. reference product	Desferal, NDA 017037
Primary clinical use	Chronic transfusional iron overload and acute iron intoxication
Biosimilar pathway	Not applicable
Main competitive products	Deferasirox and deferiprone
Main generic risk	Injectable deferoxamine products
Excipient profile	Powder is principally active pharmaceutical ingredient; reconstitution uses sterile water for injection

The product’s administration burden is a central commercial weakness. Chronic subcutaneous therapy commonly requires prolonged infusion using a portable pump. That creates opportunities for formulation and device improvements even where the active ingredient is no longer strongly protected.

What excipients are used in Desferal?

The U.S. prescribing information describes Desferal as a sterile lyophilized powder containing deferoxamine mesylate. The vial is reconstituted with Sterile Water for Injection before administration.[1]

The absence of a substantial excipient system changes the development strategy. A follow-on manufacturer does not need to reproduce a complex buffer, surfactant, preservative, or stabilizer package. The primary technical requirements are:

• Sterility assurance.
• Control of residual moisture in the lyophilized cake.
• Rapid and complete reconstitution.
• Chemical stability after reconstitution.
• Compatibility with infusion bags, syringes, tubing, pumps, and needles.
• Control of particulate matter and extractables.
• Reliable dose withdrawal from the vial.
• Appropriate labeling for storage and in-use time.

The formulation architecture reduces composition-of-matter patent exposure. It also reduces the opportunity to claim a conventional excipient combination as a meaningful product differentiator. A competitor is more likely to obtain commercial value from delivery format, stability, device integration, or manufacturing performance than from a new inactive-ingredient package.

Does Desferal contain mannitol or other stabilizing excipients?

The U.S. label identifies deferoxamine mesylate as the product component and directs reconstitution with Sterile Water for Injection.[1] A development team should not assume that a bulking agent such as mannitol, a buffer, or a preservative can be added without changing the regulatory and technical profile.

Potential excipient additions could affect:

• Osmolality and injection-site tolerability.
• Reconstitution time.
• Deferoxamine degradation.
• Chelation of trace metals during storage.
• Container interaction.
• Compatibility with infusion devices.
• Comparability to the reference product.

An excipient-free powder is therefore a strategic baseline. New excipients may support a differentiated presentation, but they also create additional chemistry, manufacturing, and controls obligations.

What excipient strategies are available for generic deferoxamine?

The strongest strategy is usually a close formulation approach that preserves the reference product’s minimal excipient profile. This reduces formulation risk and supports a conventional abbreviated application where the regulatory pathway permits reliance on the reference product.

1. Excipient-free lyophilized powder

A direct powder-for-injection product can target:

• Lower formulation complexity.
• Lower raw-material cost.
• A shorter compatibility program.
• Simpler regulatory justification.
• Easier global alignment across major markets.

The commercial disadvantage is limited differentiation. A standard vial competes mainly on price, supply reliability, quality, and contracting.

2. Buffered formulation

A buffer could improve pH control or reconstitution performance, but it would require evidence that the buffer does not change stability, tolerability, or administration characteristics. Because deferoxamine is a chelator, buffer selection must be evaluated for metal contamination and interaction with the active ingredient.

A buffered formulation may support a patent if it produces a defined stability or usability benefit. A broad claim covering deferoxamine with a conventional buffer would face vulnerability to prior-art and obviousness challenges.

3. Stabilized liquid formulation

A ready-to-use liquid could remove the reconstitution step and reduce preparation errors. Its development burden is materially higher than that of a powder.

Key technical risks include:

• Long-term chemical degradation.
• pH drift.
• Metal-catalyzed degradation.
• Adsorption to polymeric containers or tubing.
• Leachables from primary packaging.
• Preservative compatibility.
• Microbial control.
• Cold-chain or controlled-temperature requirements.

A liquid product could command a premium in hospitals if it reduces pharmacy labor and preparation time. The commercial case is strongest for emergency departments, intensive-care units, pediatric services, and high-volume transfusion centers.

4. Dual-chamber or reconstitution-integrated system

A dual-chamber vial, cartridge, or bag could separate the dry drug from the diluent until use. This approach preserves the stability of a powder while simplifying preparation.

Potential claim categories include:

• Chamber geometry.
• Breakable seal design.
• Mixing sequence.
• Reconstitution time.
• Device-specific delivery.
• Protection from light or oxygen.
• Integrated transfer mechanism.

This is more likely to generate defensible device and system patents than a conventional excipient patent.

5. Preservative-containing multidose presentation

A multidose product could reduce waste in institutions, but preservatives raise safety and regulatory questions. Deferoxamine is used in vulnerable populations, including children and patients receiving intensive treatment. A multidose strategy would need a strong microbiological and use-case justification.

The likely commercial priority is a single-use presentation with improved dose preparation rather than a preserved multidose vial.

What formulations are protected by Desferal patents?

The principal Desferal product is an old small-molecule injectable formulation. Patent protection for the original active ingredient and basic dosage form has expired or reached the end of its effective commercial life in major markets. The relevant U.S. product is listed under NDA 017037, and the Orange Book is the controlling source for current patent and exclusivity listings.[2]

No active patent position comparable to a recently launched specialty drug should be assumed for the basic deferoxamine mesylate powder. Any current freedom-to-operate review should focus on later patents covering:

• Ready-to-use deferoxamine solutions.
• Long-term liquid stability.
• Specific excipient systems.
• Prefilled syringes.
• Pump cartridges.
• Transdermal or implantable delivery.
• Dosing methods for defined patient populations.
• Combination regimens.
• Manufacturing controls and container systems.

A formulation patent must provide more than the use of a known excipient. Stronger claims would link the composition to a measurable technical result, such as a defined impurity threshold after storage, reduced adsorption, a specific reconstitution time, or improved administration-site tolerability.

When does Desferal lose exclusivity?

Desferal’s original regulatory and patent exclusivity is mature. The product does not have meaningful new chemical entity exclusivity remaining, and the basic injectable formulation is exposed to generic competition.

Protection category	Desferal status
New chemical entity exclusivity	Expired
Basic active-ingredient patent protection	Expired or commercially exhausted
Orphan exclusivity	No current basis for assuming active protection
Pediatric exclusivity	No current basis for assuming active protection
Biosimilar exclusivity	Not applicable
Current commercial barrier	Sterile injectable manufacturing, supply quality, regulatory execution, and hospital contracting

The regulatory market is therefore shaped by generic drug approval standards rather than by an originator patent cliff. A new entrant’s principal barriers are manufacturing validation, sterile fill-finish capacity, product quality, and the ability to maintain supply.

What is the Orange Book status of Desferal?

The Orange Book identifies FDA-approved drug products and, where applicable, patents and exclusivity information.[2] Desferal is associated with NDA 017037. The relevant commercial question is whether the listed reference-product presentation has any unexpired patents that could support a Paragraph IV dispute.

For an old injectable product with no meaningful active patent listing, a generic applicant may face no material Paragraph IV litigation risk. If a later-listed formulation or method-of-use patent exists, the risk depends on:

• The patent’s expiration date.
• Whether the generic label includes the patented use.
• Whether the patent is product-specific or method-specific.
• The applicant’s certification strategy.
• The reference product’s current marketing status.
• The commercial importance of the protected indication.

Orange Book review should be performed against the current FDA database rather than historic litigation summaries because listings can change through delisting, expiration, or correction.[2]

Which companies are challenging Desferal?

The competitive threat comes primarily from generic injectable deferoxamine manufacturers and alternative iron-chelation therapies. Generic companies typically compete through abbreviated applications rather than through a branded patent challenge.

Deferasirox and deferiprone have different administration profiles and safety-monitoring requirements. Deferasirox is orally administered and may be more convenient for chronic iron overload. Deferiprone is also oral but carries important hematologic monitoring requirements. Deferoxamine retains clinical relevance where parenteral chelation is preferred, rapid iron binding is required, or oral therapy is unsuitable.[1,3,4]

Product	Active ingredient	Route	Commercial advantage	Limitation
Desferal and generics	Deferoxamine mesylate	Injectable	Established use; parenteral control	Infusion burden and preparation complexity
Exjade/Jadenu and generics	Deferasirox	Oral	Greater convenience for chronic therapy	Renal, hepatic, gastrointestinal, and other monitoring considerations
Ferriprox and generics	Deferiprone	Oral	Oral administration and tissue iron activity	Neutropenia/agranulocytosis monitoring

The most credible commercial strategy is not to compete with oral chelators solely on active-ingredient price. It is to reduce the operational disadvantages of injectable deferoxamine.

What commercial opportunities exist in Desferal excipients and delivery systems?

Hospital-ready presentations

A manufacturer could develop:

• A faster-reconstituting vial.
• A premeasured diluent system.
• A ready-to-use infusion bag.
• A pharmacy-preparation kit.
• A pump-compatible cartridge.
• A unit-dose emergency presentation.

These products could reduce medication-preparation steps and improve inventory management. Their value proposition is operational rather than pharmacological.

Pediatric and specialty-care formats

Pediatric patients may benefit from lower-concentration presentations, smaller dose increments, and administration systems that reduce handling and infusion complexity. A differentiated product could target pediatric hospitals and transfusion centers through device usability, dose accuracy, and reduced preparation waste.

Global-market presentations

Excipient selection and packaging should account for geographic requirements. Key areas include:

• U.S. FDA drug approval and injectable quality requirements.
• European Union marketing authorization requirements.
• Pharmacopoeial compliance under USP, Ph. Eur., and other national standards.
• Climatic stability testing for hot and humid markets.
• Local sterile manufacturing and supply continuity.
• Diluent availability and hospital preparation practices.

An excipient-free powder can simplify global registration, but packaging must protect against moisture. A ready-to-use liquid may improve usability in developed markets while creating cold-chain or shelf-life challenges in emerging markets.

Manufacturing and supply-chain differentiation

The strongest defensible advantage may come from manufacturing rather than formulation composition. Relevant IP and know-how opportunities include:

• Low-moisture lyophilization cycles.
• Control of metal impurities.
• Reduced vial-to-vial potency variation.
• Improved cake structure and reconstitution.
• Automated visual inspection.
• Low-shear transfer methods.
• Tubing and bag compatibility.
• Sterile filtration and aseptic-fill controls.
• Packaging that limits oxygen and moisture ingress.

These improvements may support process patents, trade secrets, regulatory commitments, or customer qualification advantages. They can also reduce batch failures and supply interruptions.

What patent litigation affects Desferal?

No major current patent-litigation profile comparable to high-value oncology or biologic products is associated with the basic Desferal formulation in the principal public regulatory sources cited here. The litigation risk for a new entrant is more likely to arise from a later formulation, device, or method-of-use patent than from the original deferoxamine molecule.

A generic applicant should assess:

1. Orange Book-listed patents for NDA 017037.
2. Active U.S. patents assigned to Novartis or other deferoxamine developers.
3. Patent families covering liquid stability and delivery devices.
4. Patent term adjustment and terminal disclaimers.
5. Abbreviated application certification strategy.
6. State of any settlement or license agreement.

No settlement should be presumed without a documented agreement or court filing. For a mature injectable drug, the absence of a visible Paragraph IV dispute can indicate that the remaining patent estate is commercially weak or that the relevant patents are not listed in the Orange Book.

How strong is the Desferal patent estate?

The basic product estate is weak from a market-exclusivity perspective but potentially valuable as a platform for incremental improvements.

Estate component	Strength	Commercial implication
Deferoxamine molecule	Low	Mature active ingredient
Basic powder-for-injection formulation	Low	Generic substitution risk
Simple excipient variations	Low to moderate	Vulnerable unless tied to unexpected performance
Ready-to-use liquid	Moderate	Technical risk can support differentiated claims
Integrated delivery device	Moderate to strong	Potential device and system exclusivity
Manufacturing process	Moderate	Best protected through trade secrets and process patents
Method-of-use claims	Variable	Depends on label, indication, and enforceability
Hospital workflow presentation	Moderate	Commercial value may exceed composition value

What generic launch scenarios exist?

Price-led launch

A conventional sterile powder under an abbreviated application could enter on price. This is the fastest path to volume but offers limited margin and high exposure to hospital tenders.

Service-led launch

A company could maintain the powder formulation while offering improved supply continuity, smaller minimum orders, reliable emergency inventory, and pharmacy support. This approach requires less formulation risk.

Convenience-led launch

A ready-to-use or reconstitution-integrated presentation could pursue premium pricing. The product would need evidence that preparation time, dosing reliability, or handling safety improves enough to justify the higher cost.

Device-led launch

A pump-compatible cartridge or administration kit could target chronic subcutaneous users. The principal risks are device regulation, reimbursement, training, and possible patent separation between the drug and device.

Key Takeaways

• Desferal is deferoxamine mesylate supplied primarily as a sterile powder for injection.
• The reference formulation has a minimal excipient profile and uses Sterile Water for Injection for reconstitution.
• Basic molecule and formulation protection is mature; biosimilar risk does not apply.
• Generic injectable competition is the central exclusivity threat.
• The most attractive opportunities are ready-to-use systems, dual-chamber presentations, pump-compatible formats, and improved sterile packaging.
• A conventional excipient patent is unlikely to create strong protection unless it produces a demonstrated stability, tolerability, or usability result.
• Manufacturing controls, moisture protection, metal-impurity control, and container compatibility may provide stronger commercial barriers than a new excipient combination.
• Oral deferasirox and deferiprone compete primarily through convenience and chronic-treatment positioning.
• Current Orange Book and patent-family review remains central to any Paragraph IV or licensing strategy.

FAQs

Can a new excipient create market exclusivity for deferoxamine?

Yes, but only where the excipient system supports patentable and clinically or technically meaningful performance, such as improved stability, reduced adsorption, faster reconstitution, or better tolerability. A routine buffer or bulking agent is unlikely to provide durable protection by itself.

Is a ready-to-use deferoxamine product commercially attractive?

It can be attractive in hospitals where reconstitution labor, emergency preparation, and medication-error reduction have measurable value. The main risks are liquid stability, microbial control, packaging compatibility, and shelf-life.

Does deferoxamine qualify for a biosimilar application?

No. Deferoxamine mesylate is a chemically defined small molecule. Follow-on products generally use generic drug approval pathways rather than the biosimilar pathway.

Can a pump cartridge be patented separately from deferoxamine?

Yes. Claims may cover the cartridge, reservoir, dosing mechanism, tubing interface, reconstitution system, or integrated drug-device configuration. Drug and device patent scope must be analyzed separately.

Which market is most suitable for an improved Desferal presentation?

Hospital and specialty-care markets are the strongest targets because they bear the costs of sterile preparation, infusion logistics, inventory, and administration. Chronic transfusion centers and pediatric institutions may place the highest value on reduced preparation and infusion burden.

References

1. U.S. Food and Drug Administration. (2023). Desferal (deferoxamine mesylate) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Jadenu (deferasirox) prescribing information. FDA.

4. U.S. Food and Drug Administration. (2023). Ferriprox (deferiprone) prescribing information. FDA.

5. United States Pharmacopeia. (2024). General chapters and monographs applicable to sterile drug products and injections. USP.